Projet TClock4AD (Horizon Europe, appel à projets 2021)
Action : Doctoral Networks - Joint Doctorates
Panel : Life Sciences
Statut du projet : SIGNED

Recent Nobel Prize-winning discoveries on circadian clock (CC) have laid the foundation for ground-breaking approaches to treat many diseases, including Alzheimer’s disease (AD). AD is a current public health priority. Amplifying the demographic burden of the rising numbers of patients is the low success rate of AD therapies. Given that CC genes regulating memory, sleep, and neurodegeneration have altered expression profiles in AD, CC has recently emerged as a viable therapeutic target for new effective drugs. However, how to develop them remains a fundamental challenge. The “Targeting Circadian Clock Dysfunction in Alzheimer’s Disease” Doctoral Network (TClock4AD) is proposed to create a new generation of researchers able to face such challenge by harnessing neurobiology, medicinal chemistry, pharmaceutical nanotechnology, neuroimmunology, big data, bioinformatics, and entrepreneurship. TClock4AD will exploit unique expertise and advanced technologies at 10 leading universities, 3 research centers, a hospital, 10 non-academic institutions including SMEs, a large pharma company, a Health industry association, and a patient organization across EU, UK, Israel, USA and China. TClock4AD will deliver double degrees to 15 doctoral candidates, with triple-i knowledge/skills, broad vision and a business-oriented mindset. Their research activities will be structured around 5 scientific themes to: (1) develop novel artificial intelligence-, proteolysis targeting chimeras- and multitarget-based strategies for new CC drug candidates (2) develop novel drug delivery nanotechnologies, which take into consideration CC (3) investigate innovative in vitro (stem-cells, 3D cultures) & in vivo (Drosophila), as well as organ-on-chip techniques, for preclinical validation of CC drugs (4) get insight into the molecular mechanisms underlying CC in AD and associated drug response in mice and C. elegans models (5) develop innovative biotech business model and exploitation strategies.

Mots clés : circadian clock, alzheimer s disease, drug discovery, drug delivery, nanotechniques, organ on chip, artificial intelligence, preclinical modelling and validation

Participants :
- Ankar pharma sl (Espagne) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Clust er industrie della salute e del benessere (Italie) — Partner, associated partner, Autres, subvention : 0.0 €
- Université de Lisbonne (Portugal) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 243403.2 €
- Madrid Institute for Advanced Studies (Espagne) — Partner, beneficiary, Recherche, subvention : 251971.2 €
- Université complutense de Madrid (Espagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Barcelone (Espagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Capital Medical University (Chine) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Tel Aviv (Israël) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 271432.8 €
- Cyanagen srl (Italie) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Mario Negri Institute for Pharmacological Research (Italie) — Partner, beneficiary, Recherche, subvention : 259437.6 €
- Nostrum biodiscovery sl (Espagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 251971.2 €
- Université de Pittsburgh (Etats-Unis) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Neuroscios gmbh (Autriche) — Partner, associated partner, Autres, subvention : 0.0 €
- Université de Vérone (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 259437.6 €
- Université de Teesside (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Circadian therapeutics ltd (Royaume-Uni) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Université de Gand (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 262620.0 €
- BioTalentum (Hungary) (Hongrie) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Foundation for Research and Technology Hellas (Grèce) — Partner, beneficiary, Recherche, subvention : 240098.4 €
- Université de Wurtzbourg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 260539.2 €
- Université de Saint-Jacques-de-Compostelle (Espagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 251971.2 €
- Université de Hradec Králové (Rép. Tchèque) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 237038.4 €
- Alnylam Pharmaceuticals (United States) (Etats-Unis) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Alzheimer italia - federazione delle associazioni alzheimer d'italia (Italie) — Partner, associated partner, Autres, subvention : 0.0 €
- Université de Bologne (Italie) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 778312.8 €
- Biofabics lda (Portugal) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 243403.2 €
- She is a scientist aps (Italie) — Partner, associated partner, Autres, subvention : 0.0 €